The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The future of bispecifics for myeloma: talquetamab combinations
In this video, Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly comments on the future of bispecific antibodies for the treatment of multiple myeloma (MM). Several combination therapies containing talquetamab are being explored with the aim of improving response rates and progression-free survival (PFS), including in challenging patient populations. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The future of bispecifics, at least in the myeloma space, is likely going to be different than where we see it now. It will be in combination, and there is data emerging that, for example, talquetamab plus pomalidomide has improvement in terms of T-cell profiling, talquetamab plus daratumumab to decrease in T-regulatory cells, which also helps improve the efficacy of the bispecific...
The future of bispecifics, at least in the myeloma space, is likely going to be different than where we see it now. It will be in combination, and there is data emerging that, for example, talquetamab plus pomalidomide has improvement in terms of T-cell profiling, talquetamab plus daratumumab to decrease in T-regulatory cells, which also helps improve the efficacy of the bispecific. And we do know data from the RedirecTT-1 trial in terms of talquetamab plus teclistamab showing, again, very impressive progression-free survival and higher response rates, especially in challenging groups of patients such as those with extramedullary disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
